Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.185    0.00 (0.00%)
Bid:
0.18
Ask:
0.19
Spread: 0.01 (5.556%)
Market Cap: £1.37m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Interim Results

27 Sep 2005 12:09

Azure Holdings Plc (" Company") Interim results for the six months ended 30 June 2005 Chairman's statementIn the six months ended 30 June 2005 the Company incurred a loss before andafter taxation of ‚£74,000 (2004: ‚£229,000).Because of the lack of cash in the Company, creditors have increased butcontinue to be supportive.The directors are continuing to keep overheads to a minimum, the expenses beingthose necessary to maintain the Company's listing on AIM.The board continues to seek an acquisition for the Company.Owing to a technicality, the Company no longer has any authority to issue anyof its share capital and will therefore be convening an extraordinary generalmeeting for this purpose.Nicolas GreenstoneChairman27 September 2005Azure Holdings plcProfit and Loss Accountfor the six months ended 30 June 2005 6 months 6 months Year ended ended 30 ended 30 31 December June 2004 2004 June 2005 (unaudited) (audited) (unaudited) ‚£'000 ‚£'000 ‚£'000 Turnover - - - Administrative expenses (74) (229) (345) Operating loss (74) (229) (345) Loss on ordinary activities before (74) (229) (345)taxation Tax on loss on ordinary activities - - - Loss on ordinary activities after (74) (229) (345)taxation Retained loss for the period (74) (229) (345) Loss per ordinary share (0.15p) (0.65p) (0.86p) The profit and loss account has been prepared on the basis that all operationsare continuing operations. All recognised gains or losses are dealt withthrough the profit and loss account or statement of recognised gains andlosses.Azure Holdings plcBalance Sheetas at 30 June 2005 30 June 2005 30 June 31 December 2004 2004 (unaudited) (unaudited) (audited) ‚£'000 ‚£'000 ‚£'000 Current assets Debtors 3 14 7 Cash at bank and in hand 1 10 14 4 24 21 Creditors: amounts falling due within one (147) (81) (90)year Net current liabilities (143) (57) (69) Total assets less current liabilities (143) (57) (69) Net liabilities (143) (57) (69) Capital and reserves Called up Share Capital 5,475 5,371 5,475 Share Premium 10,279 10,279 10,279 Profit and loss account (15,897) (15,707) (15,823) Equity shareholders deficit (143) (57) (69) Azure Holdings plcCash Flow Statementfor the six months ended 30 June 2005 6 months ended 6 months ended 30 June 2005 30 June 2004 (unaudited) (unaudited) ‚£'000 ‚£'000 Net cash outflow from operating (13) (214)activities Financing Issue of ordinary shares - 105 Decrease in cash (13) (109)Azure Holdings plcNotes to the Interim Results 1. The interim results are unaudited and do not constitute statutory accounts within the meaning of section 240 of the Companies Act 1985. The figures for the year ended 31 December 2004 have been extracted from the statutory accounts filed with the registrar of companies on which the auditors gave an unqualified report. 2. The interim results have been prepared using the accounting policies set out in the statutory accounts for the year ended 31 December 2004. 3. The comparative figures for the unaudited interim results for the period ended 30 June 2004 are stated as announced on 29 September 2004. 4. Loss per share The earnings per share for the six months ended 30 June 2005 has beencalculated on the basis of the loss after taxation for the period of ‚£74,000(2004: ‚£229,000 ) and the weighted average number of shares in issue during theperiod of 48,317,569 (2004: 35,417,565). 5. The directors do not propose to pay a dividend for the period. 6. Copies of the interim results are available from the Company's registered office, One Great Cumberland Place, London, W1H 7AL. ENDAZURE HOLDINGS PLC
Date   Source Headline
11th May 20182:56 pmRNSHolding(s) in Company
8th May 201812:13 pmRNSResult of AGM
4th May 20184:40 pmRNSSecond Price Monitoring Extn
4th May 20184:35 pmRNSPrice Monitoring Extension
4th May 20184:01 pmRNSPlacing and grant of warrants
26th Apr 20182:05 pmRNSSecond Price Monitoring Extn
26th Apr 20182:00 pmRNSPrice Monitoring Extension
25th Apr 20184:40 pmRNSSecond Price Monitoring Extn
25th Apr 20184:35 pmRNSPrice Monitoring Extension
25th Apr 20187:00 amRNSEU Patent Grant for Therapeutic Compound, VAL201
20th Apr 201810:45 amEQSHardman & Co Research: ValiRx (VAL): 2017: a pivotal year
19th Apr 20187:00 amRNSGENEICE & VAL101 Update
12th Apr 20187:00 amRNSNotice of AGM
10th Apr 20187:00 amRNSFinal Results
20th Mar 20187:00 amRNSUS Patent Grant for Therapeutic Compound, VAL201
19th Mar 20187:00 amRNSHolding(s) in Company
16th Mar 20183:01 pmRNSAppointment of Broker
2nd Mar 201811:01 amRNSStatement re broker
9th Feb 201811:57 amRNSIssue of options and directors dealings
2nd Feb 20184:26 pmRNSHolding(s) in Company
25th Jan 201812:06 pmRNSHolding(s) in Company
23rd Jan 20183:30 pmRNSHolding(s) in Company
16th Jan 20187:00 amRNSValiSeek Clinical Update (VAL401)
11th Jan 20187:00 amRNSUS Patent Notice of Allowance for Compound VAL201
4th Jan 20182:29 pmRNSHolding(s) in Company
3rd Jan 20187:00 amRNSExercise of Warrants and Issue of Equity
27th Dec 201712:54 pmRNSFinal Loan Note Conversion and Issue of Equity
22nd Dec 20177:00 amRNSIssue of Equity
21st Dec 20179:16 amRNSResult of General Meeting
20th Dec 20173:58 pmRNSWarrant Exercise
20th Dec 20173:03 pmRNSWarrant Exercise
18th Dec 20178:45 amRNSWarrant Exercise
18th Dec 20177:00 amRNSre: VAL201 Clinical Trials
15th Dec 20177:00 amRNSExercise of Warrants and Issue of Equity
12th Dec 20177:00 amRNSValiSeek Clinical Development Update
11th Dec 20173:48 pmRNSLoan Note Conversion and Issue of Equity
6th Dec 20177:00 amRNSShareholder Circular and Notice of General Meeting
30th Nov 20172:38 pmRNSIssue of Equity
20th Nov 201711:23 amRNSHolding(s) in Company
15th Nov 20174:37 pmRNSYorkville CLN Conversion
11th Oct 20177:00 amRNSNotification of US Patent Allowance
5th Oct 20177:00 amRNSHolding(s) in Company
2nd Oct 20177:00 amRNSTotal Voting Rights
28th Sep 20177:00 amRNSValiSeek Clinical Development Update
27th Sep 20173:32 pmRNSHolding(s) in Company
26th Sep 20177:00 amRNSHalf-year Report
20th Sep 20173:18 pmRNSVAL201 update
19th Sep 20177:00 amRNSIssue of Equity
13th Sep 20179:34 amRNSHardman Research: GeneICE and VAL101 progress
7th Sep 20177:00 amRNSGeneICE & VAL101 Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.